...
首页> 外文期刊>Journal of pharmaceutical sciences. >Folate and CD44 Receptors Dual-Targeting Hydrophobized Hyaluronic Acid Paclitaxel-Loaded Polymeric Micelles for Overcoming Multidrug Resistance and Improving Tumor Distribution
【24h】

Folate and CD44 Receptors Dual-Targeting Hydrophobized Hyaluronic Acid Paclitaxel-Loaded Polymeric Micelles for Overcoming Multidrug Resistance and Improving Tumor Distribution

机译:叶酸和CD44受体双靶向疏水性透明质酸紫杉醇负载的聚合物胶束,克服了多药耐药性并改善了肿瘤分布

获取原文
获取原文并翻译 | 示例

摘要

The drug efflux mediated by P-glycoprotein (P-gp) transporter is one of the important factors responsible for multidrug resistance (MDR), and then the efficient intracellular drug delivery is an important strategy to overcome MDR of tumor cells. We describe and compare CD44 receptor single-targeting and folate (FA), CD44 receptors dual-targeting hyaluronic acid-octadecyl (HA-C18) micellar formulations to overcome MDR of tumor cells and to improve tumor distribution. In comparison with Taxol solution, the cytotoxicity of paclitaxel (PTX) loaded in HA-C18 and FA-HA-C18 micelles against drug-resistant tumor cells was improved significantly because of the increased intracellular delivery by active receptor-mediated endocytosis. Compared with the single-targeting micelles, dual-targeting micelles possessed better MDR-overcoming performance. Pharmacokinetic study demonstrated HA-C18 and FA-HA-C18 PTX-loaded micelles possessed much longer circulation and moderately larger AUC than Taxol solution. Above all, the tumor distribution in MCF-7 tumor-bearing mice of PTX encapsulated in HA-C18 and FA-HA-C18 micelles were 2.8 and 4.0 times higher than that of Taxol solution. It was concluded that dual-targeting FA–HA-C18 micelles demonstrate excellent MDR-overcoming ability and improved tumor distribution, and provide a novel effective nanoplatform for anticancer drug delivery in cancer chemotherapy.
机译:P-糖蛋白(P-gp)转运蛋白介导的药物外排是引起多药耐药性(MDR)的重要因素之一,因此有效的细胞内药物递送是克服肿瘤细胞MDR的重要策略。我们描述和比较CD44受体单靶向和叶酸(FA),CD44受体双靶向透明质酸-十八烷基(HA-C18)胶束配方,以克服肿瘤细胞的MDR并改善肿瘤分布。与紫杉醇溶液相比,装载在HA-C18和FA-HA-C18胶束中的紫杉醇(PTX)对耐药性肿瘤细胞的细胞毒性得到了显着改善,这是由于活性受体介导的内吞作用增加了细胞内传递。与单靶胶束相比,双靶胶束具有更好的克服MDR的性能。药代动力学研究表明,与紫杉醇溶液相比,HA-C18和FA-HA-C18 PTX加载的胶束具有更长的循环和适度更大的AUC。最重要的是,在HA-C18和FA-HA-C18胶束中封装的PTX的MCF-7荷瘤小鼠体内的肿瘤分布比紫杉醇溶液高2.8倍和4.0倍。结论是,双重靶向FA–HA-C18胶束表现出优异的MDR克服能力和改善的肿瘤分布,并为癌症化疗中的抗癌药物递送提供了新型有效的纳米平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号